Released on: August 28, 2008, 2:43 am

Press Release Author: Neil Watson

Industry: Biotech

Press Release Summary: PREMIER Biosoft International today announced the successful
completion and handover of the NEAT module to DxTerity. NEAT is an innovative
genomic testing platform for the development of simple and affordable diagnostic
tests. Software module access is available to DxTerity Diagnostic customers and
partners.


Press Release Body: Palo Alto, CA - August 28, 2008 -PREMIER Biosoft International,
a leading bioinformatics company, has recently started offering contract software
development services. As a part of this service, PREMIER Biosoft International has
successfully delivered the third and final phase of the software project for
DxTerity Diagnostics.

DxTerity Diagnostics, a provider of genomic testing solutions, has developed NEAT, a
genomic testing platform that replaces expensive enzymatic amplification techniques
with a robust chemical reaction, enabling the development of simple and affordable
diagnostic tests. NEAT has been successfully employed in the analysis of mRNA,
microRNA, rRNA, and genomic DNA.

By providing a user-friendly software solution for the probe design needs of NEAT,
DxTerity expects to lower barriers to customer adoption and speed the proliferation
of this innovative technology. The software module allows customers to quickly adapt
the NEAT technology to their individual needs, allowing the rapid development of
robust genomic assays.

"Our previous experience in developing high quality genomics design software gave us
the expertise to handle the algorithms involved in this project. With this
expertise and existing algorithms, we were able to complete the project in far less
time than working from scratch." said Kay Brown, Vice President, Business
Development, PREMIER Biosoft International.

The contract started in December 2007 and proceeded in phases with periodic
deliveries until July 2008. After the initial requirements were provided by
DxTerity, an extensive analysis was done by the PREMIER Biosoft team, consisting of
a panel of domain experts and software engineers. The highlights of the project
included developing the algorithms required for the analysis and designing the user
interface for making the product both easy-to-use and comprehensive.

The scope of the project included designing a complete NEAT probe design module that
adhered to the DxTerity probe design guidelines. For mutation specific probe
design, algorithms were developed not only to reduce assay costs, but also to enable
efficient mutation detection. This was achieved by designing the probe set such that
one probe was common for the mutation and wild type detection.


\"We decided to award this contract to PREMIER Biosoft International because of their
considerable expertise in bioinformatics and the exceptional performance of their
AlleleID software package in particular. The resulting software module streamlines
the NEAT assay design process and allows our customers to quickly develop new
genomic testing assays,\" says Bob Terbrueggen, President and CEO, DxTerity
Diagnostics.

For details about the project, please visit:
http://www.premierbiosoft.com/services/DxTerity.pdf

About PREMIER Biosoft International:
Founded in 1994, the company is a group of computer scientists and molecular
biologists dedicated to producing cutting edge intuitive software for the molecular
biologist. The goal of the company is to study the most recent innovations in
molecular biology and translate them into software products that aid biologists.
Recently, the company has completed several custom software development contracts
including one for PrimerDesign Ltd. Additional information about PREMIER Biosoft
International can be found at http://www.PremierBiosoft.com

Contact:
Arun Apte
PREMIER Biosoft International
650-856-2703
http://www.PremierBiosoft.com

About DxTerity Diagnostics, Inc.
DxTerity Diagnostics, a privately-held biotechnology company, is focused on the
development of tools and methods that make genomic testing simple, affordable and
accessible. These efforts led to the development of NEATTM, a genomic testing
platform that eliminates the need for expensive and complicated enzymatic
amplification procedure, and allows for direct analysis of many genomic targets.
NEAT has been adapted for mRNA, microRNA, rRNA and genomic DNA applications.

Contact:
Cindy Coty
DxTerity Diagnostics, Inc
310-537-7857
http://www.DxTerity.com

Web Site: http://premierbiosoft.com

Contact Details: PREMIER Biosoft International
3786 Corina Way
Palo Alto, CA 94303-4504
Fax: 650-618-1773
Phone: 888-847-7494
Email: support@premierbiosoft.com